Drug intelligence / Profile preview

Zhixueling

Development stage: Unknown
Lead developer: Guangzhou Kangchen Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Zhixueling is a Traditional Chinese Medicine (TCM) capsule developed by Conchen Pharmaceutical, a subsidiary of Consun Pharmaceutical Group. It is primarily indicated for gynecological bleeding disorders, including dysfunctional uterine bleeding and menorrhagia. The formulation is designed based on TCM principles to cool the blood and arrest hemorrhage. It is an approved oral medication in China, often used to manage excessive menstrual flow and stabilize the endometrium.

Brand names: Zhixueling Capsule
Other names: Zhixueling Jiaonang

Beyond the preview

Go deeper on Zhixueling.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhixueling.

Explore the full profile